Peer Reviewed
Rheumatology clinic
Risedronate: a new bisphosphonate on the block
Recent articles on:
Paget's Disease of Bone
Paget's Disease of Bone
Abstract
A new third generation bisphosphonate, risedronate (Actonel), is now available, joining two existing members of this therapeutic class. This article describes the evidence supporting the use of risedronate in osteoporosis and Paget’s disease.
Key Points
What do we know about risedronate?
Risedronate, a third-generation bisphosphonate, has potent antiresorptive activity in bone and is therefore of interest in treating metabolic bone disorders. Its efficacy has been evaluated extensively in osteoporosis (postmenopausal and corticosteroid-induced) and Paget’s disease.
Purchase the PDF version of this article
Already a subscriber? Login here.